At Zynerba Pharmaceuticals, we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with high unmet medical needs.
Our mission is to improve the lives of patients battling severe health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain through these therapeutics.
Our development pipeline includes patent-protected synthetic transdermal cannabinoid products, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
ZYN002 – CBD Gel
ZYN002 is the first and only synthetic CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase 2 clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee as well as in patients with Fragile X syndrome. In February 2016, the FDA granted orphan-drug designation of ZYN002 for the treatment of patients with Fragile X syndrome in the US.
ZYN001 – THC Pro-Drug Patch
ZYN001 is a pro-drug of THC that enables transdermal delivery through the skin and into the circulatory system via a patch. A Phase 1 clinical trial for ZYN001 is planned to begin in the first half of 2017.